In the current study, our results demonstrated that HMGB3, a well-known oncogene, promotes the malignant progression of ovarian cancer through activating the MAPK signaling pathway in vitro and in vivo, which may inform the development of new targeted therapy strategies for ovarian cancer. Here, HMGB3 is linked to ovarian carcinoma.